Abstract
A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have